Medexus Pharmaceuticals (TSE:MDP) Upgraded by Alliance Global Partners to Strong-Buy Rating

Key Points

• Medexus Pharmaceuticals received a "strong-buy" rating upgrade from Alliance Global Partners, indicating increased confidence in the stock's potential value.
• The stock's current price is C$2.75, with a market capitalization of C$61.57 million and a P/E ratio of 13.15.
• Medexus focuses on treatments for auto-immune diseases and pediatrics, with key products including Rasuvo and Metoject.

Medexus Pharmaceuticals (TSE:MDP - Get Free Report) was upgraded by analysts at Alliance Global Partners to a "strong-buy" rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Medexus Pharmaceuticals Trading Up 7.3%

Shares of MDP stock traded up C$0.20 on Monday, hitting C$2.95. 45,719 shares of the stock were exchanged, compared to its average volume of 73,306. The firm has a market capitalization of C$66.05 million, a P/E ratio of 14.11 and a beta of 1.96. The business has a 50-day moving average of C$2.92 and a 200 day moving average of C$2.81. Medexus Pharmaceuticals has a fifty-two week low of C$1.71 and a fifty-two week high of C$5.56.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.